Skip to main content

News & events

IBA Press Release

ElsMed, Novatec and IBA sign contract to install radiopharmaceutical production center in Georgia

The center will be equipped with a Cyclone® KIUBE offering the highest production capacity with a PET cyclotron. Louvain-La-Neuve, Belgium, October 4, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, Novatec International and ElsMed Healthcare Solutions, the leading Israeli medical-technological company, announced today that they have signed a contract for the installation of an integrated radiopharmaceutical production facility in Tbilisi, Georgia. The project will be the first of its kind in Georgia and includes the construction of an ultra-modern radiopharmaceutical facility equipped with the latest technologies such as the IBA’s Cyclone® KIUBE and Synthera®+ platform. The center will produce various types of radiopharmaceutical products and is expected to start operations in 2024. The design, construction, operation, and production processes of the facility will be developed in line with the International Atomic Energy Agency (IAEA) standards and recommendations from IBA, as well as meeting set requirements defined by the legislation of Georgia. The General Director of Novatec International, Giorgi Glonti, commented: “This unique project for an on-site production facility for radiopharmaceutical compounds will significantly boost the development of nuclear medicine in the country of Georgia. This initiative will also contribute to increasing the availability of Positron-Emission Computed Tomography (PET-CT) for a wider population. The facility will be able to fully cover the current and future demand of the Georgian market, both in terms of production and delivery of fluorodeoxyglucose (18F-FDG) as well as other artificial radioactive isotopes.”   “Nowadays, radiopharmacies need to produce an increasing amount of FDG in a limited time frame, in addition to producing numerous other compounds. The Cyclone® KIUBE is the perfect solution providing the ability to produce the widest range of radioisotopes and covers all the needs of PET radiopharmacies,” said Bruno Scutnaire, President of IBA RadioPharma Solutions.   Hen Lederman, General Manager of the ElsMed Healthcare Solutions added: “We are pleased to participate in a such unique and useful project. Our joint efforts will have a significantly positive effect in the fight against cancer in Georgia, with ElsMed being additionally involved in the facility design and training of necessary personnel, in cooperation with leading nuclear medicine centers in Israel, and will provide continuous support until project completion.”
See more
IBA et SCK CEN lancent Pantera

IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225

Louvain-La-Neuve, Belgium, 22 September 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV, which they believe will bring new hope for cancer patients. As indicated in the announcement of the R&D strategic partnership, this new company will aim to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, Pantera’s ultimate goal is to improve the accessibility of a future innovative cancer therapy based on 225Ac.   The complementarity of IBA and SCK CEN’s expertise has been demonstrated by the extensive and comprehensive R&D work that has been conducted during the last year as they work towards being able to produce large volumes of 225Ac. Pantera is now completing the technical feasibility studies before working on the final design and construction of its first facility in Mol, Belgium. Groundbreaking is expected to take place in 2024, with production starting in 2027.   Sven Van den Berghe, former Director of the Nuclear Materials Science Institute at SCK CEN, has been appointed as Chief Executive Officer, and Samy Bertrand, former technical leader for theranostics applications at IBA, takes the position of Chief Technical Officer.   Bruno Scutnaire, President of IBA RadioPharma Solutions and Chairman of the Board of Directors of Pantera, said: “Actinium-225 offers great promise for the treatment of a large variety of cancers, but only very little of the material is available worldwide today.  Once cancer treatments based on 225Ac receive approval, Pantera will focus on enabling access to a dependable supply of this promising isotope.”   Peter Baeten, Deputy Director-General of SCK CEN and Board member of Pantera, commented: “Launching Pantera was a logical choice for SCK CEN and IBA, allowing the joint-venture to leverage the innovative capabilities of both organizations, whilst utilizing the speed of an autonomous startup necessary in this fast-evolving field.”   Sven Van den Berghe, appointed Chief Executive Officer of Pantera, added: “I am excited about the opportunity to help advance the mission of Pantera to bring a new hope for cancer patients by enabling the widespread use of radioisotopes, such as actinium-225, as a basis for promising new radiopharmaceuticals. Pantera offers ’A better fight for life’, potentially bringing an effective and efficient treatment option while maximizing the quality of life of the patients, with the possibility to expand the production to other isotopes in the future.”   Actinium-225 possesses the resounding potential to treat cancers more effectively. Initial results show that the theranostic radioisotope completely eliminates cancer cells, rather than just inhibiting tumour growth. The risk of recurrence also appears to decrease. To date, extensive research and numerous studies are underway which aim to tackle both high prevalence cancers including prostate, lung, colon, breast, pancreatic, blood (leukemia and other rare forms) and kidney cancers, but also rarer forms of cancer like glioblastoma, the deadliest form of a very invasive brain cancer.  
See more
Jiming Cai, General Manager of CNRT; Chen Li,  IBA Radio Pharma Solutions Sales VP China

CNRT and IBA sign collaboration agreement to install a Cyclone® IKON in China

The Cyclone® IKON is IBA’s new high energy and high-capacity cyclotron which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, August 30, 2022 –IBA(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announced it has signed a collaboration agreement with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy. The typical end-user price for a Cyclone® IKON solution is between EUR 15 and 20 million. The Cyclone® IKON will be used for the production of novel isotopes for use in theranostics and targeted therapies, particularly for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64. These enable the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. Jiming Cai, General Manager of CNRT, commented: “We are pleased to be working with IBA to develop a stable and independent supply of commonly used medical isotopes. This will be the first Cyclone® IKON cyclotron system to be installed by IBA in China for the production of multiple radioisotopes, and is expected to be fully operational by 2025. In due course CNRT will be able to provide high-quality and efficient medical isotopes to our clients.”   Bruno Scutnaire, President of IBA RadioPharma Solutions, added: “There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. Since its launch in 2020, this is the fourth Cyclone® IKON unit sold globally and we look forward to working with CNRT over the coming months and years.”   About CNRT Chengdu New Radiomedicine Technology Co., Ltd. was established in the year 2016. It is a high-tech enterprise integrating Research and development of radiopharmaceuticals, innovation and industrialization, engaged in research, production and sales of medical isotopes, carry out demonstration research on the diagnosis and treatment of a variety of malignant tumor diseases, provide nuclear medicine technical services and scientific and technological consulting, etc. The company has built up an advanced radiopharmaceutical testing and research platform, an advanced radioactive pharmacology research platform, and an advanced radiopharmaceutical industrialization innovation platform. CNRT will ensure continuously provide high-quality, High efficiency and affordable radioactive diagnosis and treatment drugs for the patients, provide high-quality medical isotope nuclide products for the radiopharmaceutical industry, through technology, concept and products innovation. About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com   CONTACTS Soumya Chandramouli Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com   Olivier Lechien Corporate Communication Director +32 10 475 890 communication@iba-group.com   Consilium Strategic Communications Amber Fennell, Angela Gray, Lucy Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
See more

About us

Based on 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET centers for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

IBA works with you and supports you right through the whole process, from our first meeting through design, setting-up and operation. More than that, your IBA expert will support you throughout the lifetime of your radiopharmacy with trainings, updates and maintenances, to ensure the success of your project, for a sustainable future.

Read more
Who we are

Key facts

<strong>30</strong> Ci (up to)

Per production run.

For FDG production.

<strong>3</strong> (up to)

In one hotcell.

Multi tracers. Multi runs.

<strong>800</strong> +

Synthera® radiosynthesis modules installed worldwide.

<strong>300</strong> +

Cyclotrons operating and supported on 5 continents.